Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431664 | 1.00 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| Hydrochloric Acid SCHEMBL29973836 | 0.99 | CSF1R (0.98) | CSF1RKITCYP2C19LCKPGR | |
| Hydrochloric Acid SCHEMBL20166201 | 0.99 | CSF1R (0.98) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL28770362 | 0.90 | CSF1R (0.81) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1268059 | 0.89 | CSF1R (0.80) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267263 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267961 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267706 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1266888 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL12646996 | 0.88 | CSF1R (0.78) | CSF1RKITCYP2C19LCKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | claimed |
| US-7947708-B2 | Compounds modulating C-kit activity | PLEXXIKON, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-11740231-B2 | Articles of manufacture and methods related to toxicity associated with cell therapy | JUNO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11740231-B2 | Articles of manufacture and methods related to toxicity associated with cell therapy | JUNO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230172988-A1 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149458-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149458-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230053787-A1 | METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES | JUNO THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11564946-B2 | Methods associated with tumor burden for assessing response to a cell therapy | JUNO THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220031746-A1 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | disclosed |
| US-7498342-B2 | Compounds modulating c-kit activity | PLEXXIKON, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | PLEXXIKON, INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007013896-A2 | PYRROL (2,3-B) PYRIDINE DERIVATIVES PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060058340-A1 | Compounds modulating c-kit activity | PLEXXIKON INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | PLEXXIKON, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564946-B2 | Methods associated with tumor burden for assessing response to a cell therapy | TNF, TSLP, IL2 | CSF1R 53/4885KIT 8/4885CYP2C19 4232/4885 |
| US-11740231-B2 | Articles of manufacture and methods related to toxicity associated with cell therapy | TNF, IL2, PBK | CSF1R 46/4885KIT 13/4885CYP2C19 3972/4885 |
| US-20230149458-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | CSF1R 105/4885KIT 264/4885CYP2C19 4403/4885 |
| US-20060058340-A1 | Compounds modulating c-kit activity | KIT, CDC7, CDK7 | CSF1R 363/4885KIT 1/4885CYP2C19 2611/4885 |
| US-20220031746-A1 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | BCL9L, BCL9, ICOS | CSF1R 151/4885KIT 596/4885CYP2C19 3874/4885 |
| US-20230172988-A1 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | IL2, TSLP, TNF | CSF1R 56/4885KIT 10/4885CYP2C19 4216/4885 |
| US-20060058339-A1 | Compounds modulating c-kit activity and uses therefor | KIT, APC, RET | CSF1R 120/4885KIT 1/4885CYP2C19 3082/4885 |
| US-20070032519-A1 | Compounds modulating c-kit and c-fms activity and uses therefor | KIT, FLT3, FLT1 | CSF1R 7/4885KIT 1/4885CYP2C19 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.